Tagged with Samsung

Global A wave of blockbuster biologics is set to lose patent protection, creating a major inflection point for the biosimilars market in 2025 and beyond. While Europe remains the global leader in biosimilar adoption, South Korea is rapidly emerging as a powerhouse, leveraging strong government support and industry investment. However, a…

Global Originally seen as occasional service providers for the pharma industry, contract development and manufacturing organisations (CDMOs) have become vital strategic partners. Helping pharma and biotech companies advance their therapies through their outsourced services, CDMOs have demonstrated their ability to respond to the industry’s shifting priorities as well as its pre-…

Korea A roundup of some of the biggest stories from South Korean healthcare and pharma, including the government’s continuing standoff with doctors over medical reform plans; Merck’s plans for a new 300-million-euro plant; EuBiologics’s World Health Organization (WHO) prequalification for its cholera vaccine, and Samsung Biologics’ record Q1 earnings.   South…

Global Global biopharma is increasingly moving towards biologic medicines, which promise a greater impact on patient’s lives than the small-molecule drugs that preceded them, but which come with significant added costs and complexity. Against this backdrop, biologic drug developers are leaning evermore on experienced contract development and manufacturing organizations (CDMOs), of…

South Korea As big pharma continues to sharpen its focus on R&D by outsourcing other elements of the supply chain, including manufacturing, CDMOs have thrived. Samsung Biologics, one of the world’s top CDMO organizations, with revenues of USD 1.21 billion in 2021, is no exception. In response to increased demand, the firm…

Global Over the past year, PharmaBoardroom has spoken to pharma executives the world over, collecting unique perspectives from all sides of the industry. Here are the ten most-read interviews of 2022 that range from conversations with one of Korea’s top CDMOs to the American generics association and the Italian regulatory agency,…

South Korea South Korea has carved a place for itself as a dominant player in the global pharma and med-tech manufacturing industry with national companies Samsung Biologics and Celltrion leading the way. In 2019, the South Korean government announced a USD 1.7 billion five-year plan to fund biotech-related projects with the intention…

Global The Contract Development and Manufacturing Organisation (CDMO) industry has boomed in recent years, with Big Pharma increasingly focusing on its core business of R&D and outsourcing other elements of the supply chain, including manufacturing, to third-party CDMOs. Additionally, the global proliferation of biotechs – most of which lack the in-house…

Korea After a dynamic two years as CEO of Samsung Biologics, John Rim highlights some of the fundamentals behind the company’s rapid growth as a CDMO, including the creation of huge new manufacturing facilities to cope with increased demand, a dedication to carrying out technology transfers at half the speed of…

Global Recent reportage from Global Data Research and Clinical Trials Arena has ranked the world’s leading biopharma companies best positioned to take advantage of future biosimilars disruption. The ranking considers the number of jobs listed by each company mentioning biosimilars, deals conducted, and company filing mentions in the period between January…

Korea Amid global supply shortages and shipment delays for COVID-19 vaccines, South Korea has launched an ambitious 2.2 trillion won (USD 1.9 billion) investment plan to become one of the world’s five largest COVID-19 vaccine manufacturing hubs by 2025. Here, we provide a rundown of some of the key companies involved…

Korea The latest news from Korean pharma, including how Korea can put the infrastructure in place to develop a homegrown blockbuster drug; Prestige Biopharma’s move to open a vaccine facility; and Samsung Bioepis’ first steps into the Australian market.   ‘Now is best time to develop Korean blockbuster drug’ (Korea Biomedical…